MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced today announced that it will host a conference call and...

MENLO PARK, Calif., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the appointment of seasoned life sciences executive...

Patients in the Third Cohort of OPTIC will Receive a Single ADVM-022 Dose of 2 x 10 ^11 vg/eye MENLO PARK, Calif., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs...

-- Szilárd Kiss, M.D. to present an encore presentation of data from first cohort of the OPTIC phase 1 trial of ADVM-022 in wet AMD -- MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy...

-- Zero anti-VEGF rescue injections required in the first cohort and durable efficacy with median follow up of 34 weeks -- -- Sequential enrollment planned for OPTIC third and fourth cohorts ---- Company to host and webcast a discussion with key opinion leaders...

Company to Host and Webcast a Discussion with Key Opinion Leaders on Saturday, October 12 at 10:30 am PT MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting...

-- Zero anti-VEGF rescue injections required after one-time intravitreal dose of ADVM-022 -- -- Sustained improvements in retinal anatomy -- -- Was safe and well tolerated --  -- Data being presented during podium presentation at Retina Society 2019 Annual...

-- Podium presentation of 24-week data from first cohort of the OPTIC trial at Retina Society 2019 Annual Meeting on September 12, 2019 at 7:41 am BST -- -- Adverum to host a conference call and webcast to review the data presentation on September 12, 2019 at 5:30 am...

Dr. Szilard Kiss to Present at the Late Breaking Developments Session During the Retina Subspecialty Day Program on October 11, 2019 MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy...

-- Phase 1 OPTIC trial: 24-week data from first cohort to be presented at Retina Society in September; 52-week data to be presented in 1H20 -- -- Dosing of second cohort completed; 24-week data to be presented in 1H20 -- -- IND submission for ADVM-022 in diabetic...